Navigation Links
Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus

re and infection."

While previous studies had linked end-stage dementia due to HIV to the presence of infected and activated immune cells, the nature of neurological changes in earlier stages of the disease, the so-called "chronic phase," were unknown-until now.

Using simian immunodeficiency virus-infected models in the chronic phase, the research team found both virus and infiltrating lymphocytes (CD8+ T cells) in the brain. Molecular analysis revealed that the expression of several immune response genes was increased, including CCL5, which has multiple effects on neurons as well as immune cells. CCL5 was significantly upregulated throughout the course of infection, and was present in the infiltrating lymphocytes.

In addition to Fox, authors of the April 26, 2006 Journal of Neuroscience (Volume 26, Number 17) paper, titled "Host Response and Dysfunction in the CNS During Chronic SIV Infection," are: Eleanor Roberts, Salvador Huitron-Resendiz, Michael Taffe, Cecilia Marcondes, Claudia Flynn, Caroline Lanigan, Jennifer Hammond, Steven Head, and Steven Henriksen.


'"/>

Source:Public Health Agency of Canada


Page: 1 2

Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
4. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
5. Experimental RNA-based drug kills prostate cancer cells effectively and safely
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Research advances quest for HIV-1 vaccine
11. A much-needed shot in the arm for HIV vaccine development
Post Your Comments:
Breaking Biology News(10 mins):Kornberg Associates | Architects Completes UC Riverside Stem Cell Core Facility Project 2 Killer catfish? Venomous species surprisingly common, study finds 2New science estimates carbon storage potential of US lands 2PDF2Office for iWork New Utility to Convert PDF Files Directly to Native Keynote 26amp 3B Pages 26apos 3B08 26apos 3B09 Formats Ships 61205 1PDF2Office for iWork New Utility to Convert PDF Files Directly to Native Keynote 26amp 3B Pages 26apos 3B08 26apos 3B09 Formats Ships 61205 2PDF2Office for iWork New Utility to Convert PDF Files Directly to Native Keynote 26amp 3B Pages 26apos 3B08 26apos 3B09 Formats Ships 61205 3Oberthur Technologies 3A Major Security Certifications for the Identity Product Range 10700 1Oberthur Technologies 3A Major Security Certifications for the Identity Product Range 10700 2Oberthur Technologies 3A Major Security Certifications for the Identity Product Range 10700 3Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces 61197 1Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces 61197 2Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces 61197 3
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6